Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Endocrine therapy (ET) / Hormone therapy & Breast cancer / Mammacarcinoma (HR+ Her2-)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Endocrine therapy (ET) / Hormone therapy is a standard first-line treatment for advanced Breast cancer / Mammacarcinoma (HR+ Her2-)
Neven et al. 2021 Expert Review of Anticancer Therapy 21: 93-106
…

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
Burstein et al. 2019
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Gnant et al. 2022 J Clin Oncol 40: 282-293
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
Giuliano et al. 2019 Lancet Oncology 20: 1360-1369
Meta-Analysis
Review
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase III study
Mayer et al. 2021 The Lancet Oncology 22: 212-222
Ribociclib plus fulvestrant in the treatment of breast cancer
Neven et al. 2021 Expert Review of Anticancer Therapy 21: 93-106
Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
Visvanathan et al. 2019
Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update Summary
Fabian et al. 2019

7/1/2026